Bristol Myers Squibb stock: Second FDA IND accepted, EUR 53.37, up 0.40%
Published on 11/20/2026 at 08:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline milestone supports research outlook
- Evotec said the FDA accepted a second investigational new drug application under its molecular glue partnership with Bristol Myers Squibb.
- The second cereblon E3 ligase modulator is expected to enter a Phase 1 trial in 2027.
- Bristol Myers Squibb develops and commercializes medicines across oncology, hematology and other therapeutic areas.
Bristol Myers Squibb stock traded at EUR 53.37 on Lang & Schwarz at 08:33 CET on Friday, November 20, 2026, 0.40 percent above the Xetra close of Thursday, November 19.
The pharmaceutical company develops and commercializes medicines across oncology, hematology and other therapeutic areas. Its research pipeline includes molecular glue degraders, a class of compounds designed to promote the removal of selected proteins from cells.
Second candidate advances toward clinical testing
Evotec said on November 19 that the U.S. Food and Drug Administration had accepted a second Investigational New Drug application under its strategic partnership with Bristol Myers Squibb. The candidate is a cereblon E3 ligase modulator, or CELMoD, and is expected to enter a Phase 1 clinical trial in 2027.
The first candidate produced under the partnership entered a Phase 1 trial in March 2026 for advanced clear cell renal cell carcinoma. The latest milestone expands the partnered pipeline, but it does not provide clinical efficacy or safety results for the second candidate.
For the broader market setting, follow the S&P 500.
